The Challenge
Treating diseases with Biologics currently requires Injection or Infusions. This causes several disadvantages.
Patient Safety Risks
Cost
Low Patient Compliance
Challenges with Bioavailability
Drug Class
Properties
Challenges
BCS Class III/IV
oral drugs
Low permeability Low solubility
Low systemic bioavailability
Variable plasma levels
Biopharmaceuticals
High molecular weight
High solubility
Enzymatic instability
Need for parenteral administration.
Low patient compliance and adherence to
therapy
Side effects, e.g., injection site reactions (ISRs)
How Does It Work?
KriyaBio’s drug delivery technology is based on our patent-pending drug permeation enhancer KB01. KB01 is a smart tight junction modulator that interacts with epithelial tight junctions in a reversible manner. KB01 safely enables the mucosal absorption of co-administered therapies.
BIOAVAILABILITY
NON INVASIVE
Adequate Safety
Mechanism of Action: reversible opening of Tight Junctions
J. Brunner, et al., Impact of peptide permeation enhancer on tight junctions opening cellular mechanisms. Biochem. Pharmacol. (2022).
From Injection to Local Application
Oral delivery (systemic)
Increase oral bioavailability for difficult molecules (GLP1 analogues, BCS III APIs)
Transmucosal delivery (systemic)
Mucosal permeabilization for rapid systemic absorption of small molecules and peptides
Ocular delivery (e.g., AMD, DR, VD)
Transcorneal delivery of biologics avoiding tedious intravitreal injection
The Advantages
Broad range of therapeutic entities
High predictability and safety
Stand alone permeation approach
Adaptability towards formulation
Ease of manufacture
Classification of PEs
J. Brunner, S. Ragupathy, G. Borchard, Target-specific tight junction modulators. Adv. Drug Deliv. Rev. 171 (2021) 266-288. doi: 10.1016/j.addr.2021.02.008
GET IN TOUCH
If you have a project idea or simply like to learn more about us, just send us an e-mail. No matter the subject, you will hear from us quickly